Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas

Australas J Dermatol. 2018 Nov;59(4):e297-e298. doi: 10.1111/ajd.12829. Epub 2018 Apr 19.

Authors

Cathy Yunjia Zhao^{1

2}, Pablo Fernández-Peñas^{1

2}

Affiliations

¹ Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia.
² Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

PMID: 29672833
DOI: 10.1111/ajd.12829

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / adverse effects
Adalimumab / therapeutic use*
Adult
Hidradenitis Suppurativa / complications
Hidradenitis Suppurativa / diagnosis
Hidradenitis Suppurativa / drug therapy*
Humans
Male
Melanoma / complications*
Melanoma / diagnosis
Middle Aged
Patient Safety
Risk Assessment
Sampling Studies
Skin Neoplasms / complications*
Skin Neoplasms / diagnosis

Substances

Adalimumab